Research
Hormonal
Existing anti-diabetic medications, including Metformin, GLP-1 agonists, and Verapamil, exert part of their therapeutic effect by downregulating TXNIP expression.
If you are taking Metformin or GLP-1 agonists (like Ozempic or Trulicity), one of the reasons they work is that they lower TXNIP levels in your body. This helps your cells use insulin better and protects your pancreas. This is a known mechanism, not a side effect.
GoodSupportsHIGH confidence
Interestingly, metformin and Glucagon like peptide-1 (GLP-1) agonists have been shown to downregulate the expression of TXNIP, which may contribute to their therapeutic efficacy in the treatment of diabetes mellitus.
Why this rating
Supported by multiple citations in the review.
Source
TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook
Naif Mohammad Alhawiti et al. · Current Drug Targets · 2017
DOI 10.2174/1389450118666170130145514
narrative_reviewCited 237×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Inhibition of TXNIP expression or activity improves insulin sensitivity, protects pancreatic beta-cells from apoptosis, and ameliorates metabolic abnormalities in type 2 diabetes and obesity.Good
- TXNIP acts as a nutrient sensor in the hypothalamus to regulate energy expenditure and adiposity; its overexpression in Agouti-related protein (AGRP) neurons leads to diet-induced obesity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →